# Pulse Biosciences (PLSE) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PLSE
## Company Profile
- Ticker: PLSE
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: MedTech
## Stock Data
- Close: 43.32 USD
- Market cap: 1680411807.3600001 USD
- Last updated: 2026-08-12
## Business Overview
### Nanosecond Pulsed-Field Ablation
Pulse Biosciences develops the nPulse platform, which delivers proprietary nanosecond pulsed-field energy to ablate targeted tissue. The technology is designed to create nonthermal cellular effects and is being evaluated in cardiac and soft-tissue applications.
### Cardiac Catheter System
The nPulse Cardiac Catheter System is being developed for catheter-based treatment of atrial fibrillation. European feasibility data showed durable procedural success, and the U.S. NANOPULSE-AF pivotal IDE trial has begun enrolling patients.
### Surgical Atrial Fibrillation
Pulse is also developing an nPulse surgical system for concomitant atrial-fibrillation ablation during cardiac surgery. A separate IDE pivotal trial is intended to support regulatory review in this procedural setting.
### Thyroid Applications
The company is studying nanosecond PFA for benign thyroid nodules and papillary thyroid microcarcinoma. Early benign-nodule data showed durable volume reduction, while a first-in-human cancer feasibility study is underway with MD Anderson.
## Why The Stock Is Moving

As of Aug 12, 2026, PLSE closed down 2.43% at $43.32. No new same-company headline was identified in the current news window.

## Future Catalysts

- Completion of enrollment in the NANOPULSE-AF cardiac-catheter pivotal trial anticipated in early fourth-quarter 2026.
- Completion of enrollment in the papillary thyroid microcarcinoma feasibility study expected by year-end 2026.
- Completion of enrollment in the surgical atrial-fibrillation IDE pivotal trial expected by the end of the first half of 2027.

## Recent News
- 2026-08-06 20:05 EST — [Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/PLSE/pulse-biosciences-reports-business-updates-and-second-quarter-2026-financial-res-4e89618c) — Source: Pulse Biosciences
- 2026-07-30 20:05 EST — [Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference](https://biopharmsignal.com/news/PLSE/pulse-biosciences-to-present-at-canaccord-genuity-s-46th-annual-growth-conferenc-33705951) — Source: Pulse Biosciences
- 2026-07-29 11:00 EST — [Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study](https://biopharmsignal.com/news/PLSE/pulse-biosciences-surpasses-enrollment-midpoint-in-nanopulse-af-ide-pivotal-stud-f32400cf) — Source: Pulse Biosciences
- 2026-07-21 20:05 EST — [Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026](https://biopharmsignal.com/news/PLSE/pulse-biosciences-schedules-second-quarter-2026-financial-results-conference-cal-40c79816) — Source: Pulse Biosciences
- 2026-07-15 20:05 EST — [Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/PLSE/pulse-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-5413df0c) — Source: Pulse Biosciences